BACKGROUND: Statin-associated muscle symptoms (SAMS) are the major side effects reported for statins. Data from previous studies suggest that 7-29% of patients on statin had associated muscle symptoms. In the UK, there is a lack of corresponding data on SAMS and factors associated with the development of SAMS. OBJECTIVE: This analysis is aimed at establishing the prevalence of SAMS and identifying major contributory risk factors in patients attending a lipid clinic. METHODS: Clinical records of 535 consecutive patients, who visited the lipid clinic in the University Hospitals of Leicester, were studied retrospectively between 2009 and 2012. SAMS were defined by the presence of muscle symptoms with two or more different statins. Patients who reported muscle symptoms to statin with one or no rechallenge were excluded. The association of SAMS with clinical characteristics such as age and BMI, sex, smoking, excess alcohol, comorbidities, and medications was tested for statistical significance. A binomial logistic regression model was applied to adjust for risk factors significantly associated with SAMS. RESULTS: The prevalence of SAMS was found to be 11%. On unadjusted analysis, the mean age of patients who had SAMS was significantly higher than those without SAMS (59.4 ± 10.5 years vs. 50.3 ± 13.4 years, respectively, P < 0.001). Nonsmokers were more likely to develop SAMS in comparison to active smokers (P = 0.037). Patients taking antihypertensive medications were more likely to develop SAMS (P = 0.010). In binomial logistic regression analysis, only age was positively and significantly associated with SAMS after adjusting for other risk factors (β = 0.054, P = 0.001). CONCLUSION: To the best of our knowledge, this study is the largest cohort of patients with SAMS in the United Kingdom. Our data suggest that the prevalence of SAMS is 11% and increased age is a risk factor associated with the development of SAMS in our cohort of patients.
BACKGROUND: Statin-associated muscle symptoms (SAMS) are the major side effects reported for statins. Data from previous studies suggest that 7-29% of patients on statin had associated muscle symptoms. In the UK, there is a lack of corresponding data on SAMS and factors associated with the development of SAMS. OBJECTIVE: This analysis is aimed at establishing the prevalence of SAMS and identifying major contributory risk factors in patients attending a lipid clinic. METHODS: Clinical records of 535 consecutive patients, who visited the lipid clinic in the University Hospitals of Leicester, were studied retrospectively between 2009 and 2012. SAMS were defined by the presence of muscle symptoms with two or more different statins. Patients who reported muscle symptoms to statin with one or no rechallenge were excluded. The association of SAMS with clinical characteristics such as age and BMI, sex, smoking, excess alcohol, comorbidities, and medications was tested for statistical significance. A binomial logistic regression model was applied to adjust for risk factors significantly associated with SAMS. RESULTS: The prevalence of SAMS was found to be 11%. On unadjusted analysis, the mean age of patients who had SAMS was significantly higher than those without SAMS (59.4 ± 10.5 years vs. 50.3 ± 13.4 years, respectively, P < 0.001). Nonsmokers were more likely to develop SAMS in comparison to active smokers (P = 0.037). Patients taking antihypertensive medications were more likely to develop SAMS (P = 0.010). In binomial logistic regression analysis, only age was positively and significantly associated with SAMS after adjusting for other risk factors (β = 0.054, P = 0.001). CONCLUSION: To the best of our knowledge, this study is the largest cohort of patients with SAMS in the United Kingdom. Our data suggest that the prevalence of SAMS is 11% and increased age is a risk factor associated with the development of SAMS in our cohort of patients.
Authors: G B John Mancini; A Yashar Tashakkor; Steven Baker; Jean Bergeron; David Fitchett; Jiri Frohlich; Jacques Genest; Milan Gupta; Robert A Hegele; Dominic S Ng; Glen J Pearson; Janet Pope Journal: Can J Cardiol Date: 2013-09-29 Impact factor: 5.223
Authors: Khoa A Nguyen; Lang Li; Deshun Lu; Aida Yazdanparast; Lei Wang; Rolf P Kreutz; Elizabeth C Whipple; Titus K Schleyer Journal: Eur J Clin Pharmacol Date: 2018-05-22 Impact factor: 2.953
Authors: Erik S Stroes; Paul D Thompson; Alberto Corsini; Georgirene D Vladutiu; Frederick J Raal; Kausik K Ray; Michael Roden; Evan Stein; Lale Tokgözoğlu; Børge G Nordestgaard; Eric Bruckert; Guy De Backer; Ronald M Krauss; Ulrich Laufs; Raul D Santos; Robert A Hegele; G Kees Hovingh; Lawrence A Leiter; Francois Mach; Winfried März; Connie B Newman; Olov Wiklund; Terry A Jacobson; Alberico L Catapano; M John Chapman; Henry N Ginsberg Journal: Eur Heart J Date: 2015-02-18 Impact factor: 29.983
Authors: Maciej Banach; Manfredi Rizzo; Peter P Toth; Michel Farnier; Michael H Davidson; Khalid Al-Rasadi; Wilbert S Aronow; Vasilis Athyros; Dragan M Djuric; Marat V Ezhov; Robert S Greenfield; G Kees Hovingh; Karam Kostner; Corina Serban; Daniel Lighezan; Zlatko Fras; Patrick M Moriarty; Paul Muntner; Assen Goudev; Richard Ceska; Stephen J Nicholls; Marlena Broncel; Dragana Nikolic; Daniel Pella; Raman Puri; Jacek Rysz; Nathan D Wong; Laszlo Bajnok; Steven R Jones; Kausik K Ray; Dimitri P Mikhailidis Journal: Arch Med Sci Date: 2015-03-14 Impact factor: 3.318
Authors: Kelvin Shenq Woei Siew; Muhammad Imran Abdul Hafidz; Fatimah Zahrah Binti Mohd Zaidan; Mohd Firdaus Bin Hadi Journal: Eur Heart J Case Rep Date: 2022-02-22